Aromatase inhibitors (AIs) increase the risk of bone loss and fracture. Guidelines recommend routine bone density screening for women on AIs, but there are few data regarding the incorporation of these guidelines into clinical practice. We assessed bone density testing in a community-based cohort of breast cancer patients treated with AIs. By means of encounter and pharmacy data from WellPoint plans in the HealthCore Integrated Research Database, we assessed bone density testing among 9,138 women aged ≥50 years with breast cancer who were treated with AIs between 2002 and 2008. We used multivariable logistic regression to identify factors associated with baseline bone density testing in women initiating an AI, and among a subset of 2,086 women treated with AIs for at least 2 years, with testing during the first 2 years of therapy. Only 41.6 % of women underwent bone density testing when initiating AI therapy. Rates of bone density testing increased over time, but were lower for women who were older, lived in the Northeast (vs. other regions), had been treated with prior proton pump inhibitor or tamoxifen therapy, lived in areas with lower educational attainment, or were enrolled in a health maintenance organization (vs. other insurance types) (all P < 0.05). Among women treated with AIs for at least 2 years, 59.9 % of women underwent bone density testing during the first 2 years of AI therapy. Rates of testing were lower for women living in the Midwest or West (vs. Northeast), living in areas with lower education levels, enrolled in health maintenance organizations (vs. other insurance types), and with prior tamoxifen use. In conclusion, most women initiating AI therapy, and 40 % of those on long-term therapy, did not undergo recommended bone density evaluation in this community-based population. Attention is needed to insure that unnecessary fractures are avoided in breast cancer patients taking AIs.
Aromatase inhibitor Breast cancer Bone density
This is a preview of subscription content, log in to check access.
This work was funded by the National Institutes of Health (R01 CA127652 to Dr. Keating).
Dr. Eric Winer received an honorarium from Novartis for consulting work. The other authors have no disclosures.
Hillner BE, Ingle JN, Chlebowski RT et al (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042–4057PubMedCrossRefGoogle Scholar
National Comprehensive Cancer Network NCC (2005) Breast Cancer Clinical Practice Guidelines. In Edition 2005.v1Google Scholar
Gralow JR, Biermann JS, Farooki A et al (2009) NCCN Task Force Report: bone health in cancer care. J Natl Compr Canc Netw 7(Suppl 3):S1–S32 quiz S33–35PubMedGoogle Scholar
Theriault RL, Biermann JS, Brown E et al (2006) NCCN Task Force Report: bone health and cancer care. J Natl Compr Canc Netw 4(Suppl 2):S1–S20 quiz S21–22Google Scholar
Hadji P, Body JJ, Aapro MS et al (2008) Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 19:1407–1416PubMedCrossRefGoogle Scholar
Hadji P, Aapro M, Body J et al (2011) Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol 22:2546PubMedCrossRefGoogle Scholar
Neuner JM, Binkley N, Sparapani RA et al (2006) Bone density testing in older women and its association with patient age. J Am Geriatr Soc 54:485–489PubMedCrossRefGoogle Scholar
Klabunde CN, Potosky AL, Legler JM, Warren JL (2000) Development of a comorbidity index using physician claims data. J Clin Epidemiol 53:1258–1267PubMedCrossRefGoogle Scholar
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383PubMedCrossRefGoogle Scholar
Lau YT, Ahmed NN (2012) Fracture risk and bone mineral density reduction associated with proton pump inhibitors. Pharmacotherapy 32:67–79PubMedGoogle Scholar
Santen RJ (2011) Clinical review: effect of endocrine therapies on bone in breast cancer patients. J Clin Endocrinol Metab 96:308–319PubMedCrossRefGoogle Scholar
Earle CC, Burstein HJ, Winer EP, Weeks JC (2003) Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol 21:1447–1451PubMedCrossRefGoogle Scholar
Snyder CF, Frick KD, Kantsiper ME et al (2009) Prevention, screening, and surveillance care for breast cancer survivors compared with controls: changes from 1998 to 2002. J Clin Oncol 27:1054–1061PubMedCrossRefGoogle Scholar
Arimidex, Tamoxifen, Alone or in Combination Trialists’ Group (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 359:2131–2139PubMedCrossRefGoogle Scholar
Thurlmann B, Keshaviah A, Mouridsen H, Mauriac L (2005) BIG 1–98: randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. J Clin Oncol 23:511Google Scholar
Goss P, Ingle J, Martino S et al (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793–1802PubMedCrossRefGoogle Scholar
Jakesz R, Jonat W, Gnant M, Mittlboeck M (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from ABCSG trial 8 and the ARNO 95 trial. Lancet 366:455–462PubMedCrossRefGoogle Scholar
Arimidex, Tamoxifen, Alone or in Combination Trialists’ Group (2005) Results of the ATAC (Arimidex, Tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365:60–62PubMedCrossRefGoogle Scholar
Llombart A, Frassoldati A, Paija O et al (2012) Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial. Clin Breast Cancer 12:40–48PubMedCrossRefGoogle Scholar
Eidtmann H, de Boer R, Bundred N et al (2010) Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 21:2188–2194PubMedCrossRefGoogle Scholar
Bundred NJ, Campbell ID, Davidson N et al (2008) Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results. Cancer 112:1001–1010PubMedCrossRefGoogle Scholar
Brufsky AM, Harker WG, Beck JT et al (2012) Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer 118:1192–1201PubMedCrossRefGoogle Scholar
Iwase H (2008) Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer. Breast Cancer 15:278–290PubMedCrossRefGoogle Scholar
Bilezikian JP (2009) Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. Am J Med 122:S14–S21PubMedCrossRefGoogle Scholar
Edwards BJ, Raisch DW, Shankaran V et al (2011) Cancer therapy associated bone loss: implications for hip fractures in mid-life women with breast cancer. Clin Cancer Res 17:560–568PubMedCrossRefGoogle Scholar
Hershman DL, Shao T, Kushi LH et al (2010) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126:529–537PubMedCrossRefGoogle Scholar